Anti-HBV activity and tolerability of clevudine, a novel nucleoside analogue: initial results of a phase I/II 28-day study: Patrick Marcellin, Hopital Beaujon, Clichy, NC France; Daniel Sereni, Hopital St Louis, Paris France; Stephen Sacks, Viridae, Vancouver Canada; Jean-Pierre Bronowicki, Hopital de Brabois, Nancy France; Nirupama D Sista, Lei Fang, Triangle Pharmaceuticals, Durham, NC; Byung Chul Yoo, Chung-Ang University Hospital, Seoul Korea; Franck S Rousseau, Triangle Pharmaceuticals, Durham, NC; Hyo-Suk Lee, Seoul National University Hospital, Seoul Korea